Hello,

Welcome to our flagship newsletter, MarketBeat Daily Ratings.

We'll deliver the latest "Buy" and "Sell" ratings from Wall Street's top-rated analysts directly to your inbox each morning.

But first, we need you to do two quick things:

1. Hit reply, and send a simple "Yes." Just one word. This tells Google (and other emails providers) that you actually want to get our newsletter.

2. After that, this link to confirm your subscription. That will tell us that you received our welcome email and that we should start sending your daily report. 

Confirm your subscription here.

After you have completed these two steps, we would like to gift you a free copy of one of our most popular investing reports: 7 Stocks to Buy and Hold Forever. You can download the report with this link.

Thank you again for subscribing. We look forward to being an important part of your investing journey

Matthew Paulson
Founder and CEO, MarketBeat.

P.S. If you didn’t intend to subscribe, no problem—you can unsubscribe with this link.

(ARReply-161)

Curaleaf Tries To Roll Up Aurora In a Hostile Cannabis Bid

Submitted by Jeffrey Neal Johnson. Publication Date: 9/15/2026.

Cross-border consolidation in the cannabis industry has moved from executive speculation to aggressive dealmaking. As regulatory hurdles begin to clear across North America and Europe, operators are moving quickly to strengthen their finances and expand internationally.

Curaleaf Holdings, Inc. (OTCMKTS: CURLF) bypassed Aurora Cannabis management and took an acquisition proposal directly to Aurora Cannabis Inc. (NASDAQ: ACB) shareholders. By offering a cash-and-stock package valued at about $4 per share, Curaleaf is attempting to build an international commercial footprint spanning 17 countries.

Tomorrow it's $29.97 (Ad)

Bill Poulos is giving away his Simple Options Trading For Beginners book through a temporary link. Once that link expires, it returns to its usual price of $29.97.

The content stays the same - plain-English lessons and a handful of proven techniques - only the price changes. Waiting means paying for something you could have gotten for free.

Download your free copy before the link expires today.

For investors tracking capital flows and federal policy changes, this hostile bid signals that the era of fragmented regional cannabis operators may be coming to a close. The proposed deal also shows how industry leaders are using their financial strength to gain scale ahead of expected federal reforms.

Curaleaf Goes to the Grassroots

The deal began when Curaleaf went public with its formal tender offer, appealing directly to shareholders after private merger discussions stalled. The proposal offers 0.3463 Curaleaf common shares and 75 cents in cash for each Aurora Cannabis share tendered. Based on Aurora Cannabis's unaffected 30-day volume-weighted average price (VWAP) of $2.76 on Aug. 10, 2026, the bid implies a $4-per-share purchase price and a 45% acquisition premium.

Shareholder tensions escalated on Sept. 14, 2026, when Curaleaf filed an application with the Alberta Securities Commission seeking an order to cease trading or halt Aurora Cannabis's active at-the-market (ATM) equity distribution facility. Curaleaf contends that Aurora Cannabis leadership is using continuous share issuances as a defensive maneuver to dilute shareholder voting power and entrench management.

Over recent years, Aurora Cannabis has raised more than $400 million through equity offerings, selling shares for as little as $2.60 in July 2026. Curaleaf Chairman Boris Jordan scheduled an open shareholder webcast for Sept. 17, 2026, to present the strategic case directly to investors ahead of the Dec. 1, 2026, tender expiration.

Merging High Sales With Low Leverage

Beneath the boardroom fight lies a compelling balance-sheet transaction. Curaleaf operates at substantial scale in the domestic market, recording annual net revenue of about $1.27 billion. In its latest quarterly report, the company delivered $340.1 million in revenue and 5 cents in adjusted earnings per share, outperforming consensus estimates. Continued expansion in state-level retail has left Curaleaf with a debt-to-equity ratio of 1.06 and operating cash flow of 17 cents per share.

In contrast, Aurora Cannabis provides a cash-rich, low-leverage balance sheet. The company has a minimal debt-to-equity ratio of 0.03 and a current ratio of 5.36, along with a book value of $6.27 per share. Despite these balance-sheet strengths, Aurora Cannabis faces operational headwinds, including an annual revenue base of about $247.82 million, a negative net profit margin of 32.26%, and multiquarter top-line contraction.

Acquiring Aurora Cannabis would allow Curaleaf to purchase the company at roughly 0.60 times book value. Pro forma estimates indicate that the combined organization would generate more than $1.5 billion in annual revenue and approximately $350 million in adjusted EBITDA. Eliminating duplicative public-listing expenses, centralizing supply-chain logistics, and streamlining corporate overhead are expected to produce at least $40 million in annualized cost efficiencies and operational savings.

German Exports Meet American Reform

The timing of this takeover bid aligns with regulatory tailwinds in both North America and Europe. In the U.S., administrative momentum surrounding the reclassification of cannabis under Schedule III of the Controlled Substances Act could eliminate Internal Revenue Code Section 280E.

This federal tax provision prevents cannabis operators from deducting ordinary business expenses, frequently pushing effective corporate tax burdens above 70%. Removing Section 280E would immediately improve Curaleaf's cash flow, easing the capital required to fund the 75-cent cash component of the tender offer.

At the same time, Aurora Cannabis provides a turnkey medical export platform that U.S. operators cannot build domestically under existing federal restrictions. The company holds established distribution agreements across mature medical markets, including Germany, the United Kingdom, Poland, and Australia.

Following recent German medical cannabis reforms that simplified patient prescription procedures, demand for standardized, pharmaceutical-grade imports has expanded significantly. Combining Curaleaf's domestic retail presence with Aurora Cannabis's international commercial network would provide immediate access to European health care channels.

The Green Spread: Why MSOS Call Volume Points to a Re-Rating

Public-market pricing reflects growing confidence in cross-border consolidation. With Aurora Cannabis shares trading near $3.80, the stock sits at a narrow 5% discount to the implied $4 acquisition price. This tight arbitrage spread suggests that the market anticipates either successful deal completion or a sweetened bid from the acquirer.

Institutional sentiment is also visible across sector exchange-traded funds. AdvisorShares Pure US Cannabis ETF (NYSEARCA: MSOS) saw a sharp surge in derivatives positioning, recording daily volume of 52,583 contracts. Options flows showed an extreme call-side skew, with 46,416 call options trading against only 6,167 put options, resulting in an 88.3% call ratio.

Because Curaleaf accounts for about 21.6% of the fund's underlying exposure through direct stock and swap contracts, institutional desks appear to be using the ETF to position for broader valuation re-ratings. Elevated short interest of roughly 9.79 million shares adds fuel for a potential short-covering advance if consolidation gains momentum.

Pruning Out the Risk and Weighing the Upside

Investors monitoring the cannabis sector should view this hostile bid as a potential catalyst for widespread industry realignments. Aurora Cannabis shareholders must weigh the potential liquidity of a 45% premium against management's standalone turnaround timeline before the Dec. 1, 2026, deadline. Immediate investor focal points include the Sept. 17 executive Q&A, the pending Alberta Securities Commission ruling on the ATM facility, and upcoming quarterly corporate filings.

While integration challenges and potential regulatory delays in cross-border approvals remain risks, the commercial logic of combining scale, international reach, and balance-sheet liquidity is difficult to dismiss. Investors seeking exposure to sector-wide consolidation might consider Curaleaf for its established market presence or monitor Aurora Cannabis to evaluate event-driven arbitrage spreads. Those seeking broader exposure without single-operator regulatory risk may consider diversified funds such as the AdvisorShares Pure US Cannabis ETF on minor price pullbacks as federal policy shifts unfold.